Key Performance Indicators to criteria 8

Key Performance Indicator GRI SRS-102-35: Renumeration policies
The reporting organization shall report the following information:

a. Remuneration policies for the highest governance body and senior executives for the following types of remuneration:
i. Fixed pay and variable pay, including performance-based pay, equity-based pay, bonuses, and deferred or vested shares;
ii. Sign-on bonuses or recruitment incentive payments;
iii. Termination payments;
iv. Clawbacks;
v. Retirement benefits, including the difference between benefit schemes and contribution rates for the highest governance body, senior executives, and all other employees.

b. How performance criteria in the remuneration policies relate to the highest governance body’s and senior executives’ objectives for economic, environmental, and social topics.

The detailed compensation report for BRAIN's ececutive management and supervisory board is published within our corporate annual report on pages 91ff. 
https://www.brain-biotech.com/content/files/financial_publications/2021-22/BRAIN_Biotech_AG_Annual_Report_2020-21_EN.pdf

We pay all of our employees industry standard salaries.

Key Performance Indicator GRI SRS-102-38: Annual total compensation ratio
The reporting organization shall report the following information:

a. Ratio of the annual total compensation for the organization’s highest-paid individual in each country of significant operations to the median annual total compensation for all employees (excluding the highest-paid individual) in the same country.

The BRAIN group tries to balance industry level and fair compensation with its ambition to stay competitive on the level of personnel costs. 

The average monthly compensation in the AG for executive board members excluding variable compensation has been factor 4.8 compared to the average employee salary. Including variable compensation factor 7.2.